An undefined cystatin CsCPI1 from tea plant Camellia sinensis harbors antithrombotic activity

Fang, Mingqian; Cha, Jong-Ho; Wang, Hao Ching; Ye, Peng; Bi, Chen; Chen, Mengrou; Yang, Wenhao; Yan, Xiuwen

doi:10.1016/j.biopha.2023.114285

Cited by 4 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The modes of antithrombotic action may be due to antiplatelet activities instead of anticoagulation ones ( 26 ). In addition to GTC, EGCG, or EGC, CsCPI1, which is a cysteine proteinase inhibitor (CPI) from green tea, also promotes antithrombotic activity by inhibiting platelet aggregation ( 27 ). Furthermore, epigallocatechin (EGC) in green tea was demonstrated to have both significant anticoagulation and antiplatelet activities in vivo in another research ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

The role of green tea intake in thromboprophylaxis of venous thromboembolism in patients with cancer

Yao,

Qiao,

Cheng

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

BackgroundGreen tea intake has been reported to improve the clinical outcomes of patients with cardiovascular diseases or cancer. It may have a certain role in the development of venous thromboembolism (VTE) among cancer patients. The current study aimed to address this issue, which has been understudied.MethodsWe carried out a retrospective study to explore the role of green tea intake in cancer patients. Patients with and without green tea intake were enrolled in a 1:1 ratio by using propensity scoring matching. The primary and secondary outcomes were VTE development and mortality 1 year after cancer diagnosis, respectively.ResultsThe cancer patients with green tea intake (n = 425) had less VTE development (10 [2.4%] vs. 23 [5.4%], p = 0.021), VTE-related death (7 [1.6%] vs. 18 [4.2%], p = 0.026), and fatal pulmonary embolism (PE) (3 [0.7%] vs. 12 [2.8%], p = 0.019), compared with those without green tea intake (n = 425). No intake of green tea was correlated with an increase in VTE development (multivariate hazard ratio (HR) 1.758 [1.476–2.040], p < 0.001) and VTE-related mortality (HR 1.618 [1.242–1.994], p = 0.001), compared with green tea intake. Patients with green tea intake less than 525 mL per day had increased VTE development (area under the curve (AUC) 0.888 [0.829–0.947], p < 0.001; HR1.737 [1.286–2.188], p = 0.001) and VTE-related mortality (AUC 0.887 [0.819–0.954], p < 0.001; HR 1.561 [1.232–1.890], p = 0.016) than those with green tea intake more than 525 mL per day. Green tea intake caused a decrease in platelet (p < 0.001) instead of D-dimer (p = 0.297). The all-cause mortality rates were similar between green tea (39 [9.2%]) and non-green tea (48 [11.3%]) intake groups (p = 0.308), whereas the VTE-related mortality rate in the green tea intake group (7 [1.6%]) was lower than that of the non-green tea intake group (18 [4.2%]) (p = 0.026). The incidences of adverse events were similar between the green tea and non-green tea intake groups.ConclusionIn conclusion, the current study suggests that green tea intake reduces VTE development and VTE-related mortality in cancer patients, most likely through antiplatelet mechanisms. Drinking green tea provides the efficacy of thromboprophylaxis for cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of green tea intake in thromboprophylaxis of venous thromboembolism in patients with cancer

Yao,

Qiao,

Cheng

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Male C57BL/6J mice (6 weeks old, n = 6-7) were first anesthetized and fixed on a thermalcontrolled operating table (Harvard Apparatus, USA) to maintain a normal body temperature (37 °C) during tMCAO surgery. Wire bolus (1623-50A4, CNONTECH, China) inserted from external carotid artery (ECA) into internal carotid artery (ICA), performing as previously reported (Fang et al, 2023a), 0.9 % saline (control), and LE6 (0.5 or 2 mg/kg) were i.v. injected 15 minutes before the wired was removed.…”

Section: Min Transient Middle Cerebral Artery Occlusion (Tmcao) Modelmentioning

confidence: 99%

Bat-derived oligopeptide LE6 inhibits the contact–kinin pathway and harbors anti-thromboinflammation and stroke potential.

Cha,

Yang,

Gao

et al. 2024

Zoological Research

View full text Add to dashboard Cite

Thrombosis and inflammation predominantly contribute to the onset and progression of ischemic stroke. The contact-kinin pathway initiated by plasma kallikrein (PK) and activated factor XII (FXIIa), functions bidirectionally with the coagulation and inflammation cascade response, thus emerging a direction for the development of therapeutic drugs for ischemic stroke. In this study, we identified a bat (Myotis myotis Borkhausen)-derived oligopeptide LE6 (Leu-Ser-Glu-Glu-Pro-Glu, 702 Da), demonstrating potential in stroke therapy by targeting the inhibition of the contact kinin pathway. Notably, LE6 demonstrating potential in stroke therapy by exerting an inhibitory effect on PK and FXIIa, with inhibition constants of 43.97 μM and 6.37 μM, respectively. In vitro, analyses revealed that LE6 prolonged plasma recalcification time and activated partial thromboplastin time. And in murine models, LE6 inhibited carrageenan-induced mouse tail thrombosis, FeCl 3 -induced carotid artery thrombosis, and photochemically induced intracerebral thrombosis. Furthermore, LE6 significantly decreased inflammation and stroke injury in transient middle cerebral artery occlusion models. Importantly, the low toxicity, hemolytic, and low bleeding potential of LE6 and together with its synthetic simplicity, underscore its potential clinical availability. In conclusion, LE6, as an inhibitor of FXIIa and PK, is beneficial in stroke therapy by reducing inflammation and inhibiting thrombus formation.

show abstract

Kallikrein inhibitor derived from immunoglobulin heavy chain junction region possesses anti-thromboinflammation potential

Yang,

Li,

Deng

et al. 2024

Pharmacological Research

View full text Add to dashboard Cite

An undefined cystatin CsCPI1 from tea plant Camellia sinensis harbors antithrombotic activity

Cited by 4 publications

References 43 publications

The role of green tea intake in thromboprophylaxis of venous thromboembolism in patients with cancer

The role of green tea intake in thromboprophylaxis of venous thromboembolism in patients with cancer

Bat-derived oligopeptide LE6 inhibits the contact–kinin pathway and harbors anti-thromboinflammation and stroke potential.

Kallikrein inhibitor derived from immunoglobulin heavy chain junction region possesses anti-thromboinflammation potential

Contact Info

Product

Resources

About